Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes

Soumyarwit Manna, James J. Augsburger, Zelia Correa, Marwan F. Al-Rjoub, Marepalli B. Rao, Rupak K. Banerjee

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study is to noninvasively evaluate the safety and toxicity of a chitosan (CS) and polylactic acid (PLA)-based sustained-release methotrexate (MTX) intravitreal microimplant in normal rabbit eyes using electroretinography (ERG). Methods: PLA-coated CS-based microimplants containing 400 μg of MTX and placebo microimplants (without drug) were surgically implanted in the vitreous of the right and the left eyes, respectively, in each of the 8 New Zealand rabbits using minimally invasive technique. At each predetermined time points (days 5, 12, 19, and 33), ERG was conducted on 2 rabbits to evaluate the safety of the microimplants administered in each eye. ERG was carried out using 2 protocols, scotopic and photopic, on each eye prior to surgery (PS) and prior to euthanasia (PE) conditions. The safety of the microimplants was assessed using statistical analysis of the ERG data (B/A ratio analysis, oscillatory potential analysis, and Naka-Rushton analysis) and subsequently quantifying and comparing functional integrity of the retina between the PS and PE conditions of each eye. Results: Statistical analysis of the ERG data showed no change in retinal functional integrity because of the PLA-coated CS-based MTX microimplant and the placebo microimplant. ERG analysis also revealed absence of any evident bioelectrical dysfunction caused by the microimplants. Conclusion: ERGs were performed to determine whether the microimplants containing MTX and the placebo microimplants were associated with any profound retinal bioelectrical dysfunction that might be attributable to toxicity not apparent on histological studies of such eyes. The results shown in this report indicate that there were no such evident adverse effects of the microimplants or contained drug.

Original languageEnglish (US)
Pages (from-to)583-594
Number of pages12
JournalJournal of Ocular Pharmacology and Therapeutics
Volume32
Issue number9
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Electroretinography
Methotrexate
Rabbits
Chitosan
Statistical Data Interpretation
Euthanasia
Placebos
Safety
Pharmaceutical Preparations
Retina
poly(lactic acid)

Keywords

  • chitosan
  • Electroretinogram
  • intravitreal
  • methotrexate
  • polylactic acid
  • sustained drug delivery

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes. / Manna, Soumyarwit; Augsburger, James J.; Correa, Zelia; Al-Rjoub, Marwan F.; Rao, Marepalli B.; Banerjee, Rupak K.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 32, No. 9, 01.11.2016, p. 583-594.

Research output: Contribution to journalArticle

Manna, Soumyarwit ; Augsburger, James J. ; Correa, Zelia ; Al-Rjoub, Marwan F. ; Rao, Marepalli B. ; Banerjee, Rupak K. / Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes. In: Journal of Ocular Pharmacology and Therapeutics. 2016 ; Vol. 32, No. 9. pp. 583-594.
@article{0a624640d25d40b794c44b1b0091313a,
title = "Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes",
abstract = "Purpose: The purpose of this study is to noninvasively evaluate the safety and toxicity of a chitosan (CS) and polylactic acid (PLA)-based sustained-release methotrexate (MTX) intravitreal microimplant in normal rabbit eyes using electroretinography (ERG). Methods: PLA-coated CS-based microimplants containing 400 μg of MTX and placebo microimplants (without drug) were surgically implanted in the vitreous of the right and the left eyes, respectively, in each of the 8 New Zealand rabbits using minimally invasive technique. At each predetermined time points (days 5, 12, 19, and 33), ERG was conducted on 2 rabbits to evaluate the safety of the microimplants administered in each eye. ERG was carried out using 2 protocols, scotopic and photopic, on each eye prior to surgery (PS) and prior to euthanasia (PE) conditions. The safety of the microimplants was assessed using statistical analysis of the ERG data (B/A ratio analysis, oscillatory potential analysis, and Naka-Rushton analysis) and subsequently quantifying and comparing functional integrity of the retina between the PS and PE conditions of each eye. Results: Statistical analysis of the ERG data showed no change in retinal functional integrity because of the PLA-coated CS-based MTX microimplant and the placebo microimplant. ERG analysis also revealed absence of any evident bioelectrical dysfunction caused by the microimplants. Conclusion: ERGs were performed to determine whether the microimplants containing MTX and the placebo microimplants were associated with any profound retinal bioelectrical dysfunction that might be attributable to toxicity not apparent on histological studies of such eyes. The results shown in this report indicate that there were no such evident adverse effects of the microimplants or contained drug.",
keywords = "chitosan, Electroretinogram, intravitreal, methotrexate, polylactic acid, sustained drug delivery",
author = "Soumyarwit Manna and Augsburger, {James J.} and Zelia Correa and Al-Rjoub, {Marwan F.} and Rao, {Marepalli B.} and Banerjee, {Rupak K.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1089/jop.2016.0006",
language = "English (US)",
volume = "32",
pages = "583--594",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Noninvasive Electroretinography Assessment of Intravitreal Sustained-Release Methotrexate Microimplants in Rabbit Eyes

AU - Manna, Soumyarwit

AU - Augsburger, James J.

AU - Correa, Zelia

AU - Al-Rjoub, Marwan F.

AU - Rao, Marepalli B.

AU - Banerjee, Rupak K.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose: The purpose of this study is to noninvasively evaluate the safety and toxicity of a chitosan (CS) and polylactic acid (PLA)-based sustained-release methotrexate (MTX) intravitreal microimplant in normal rabbit eyes using electroretinography (ERG). Methods: PLA-coated CS-based microimplants containing 400 μg of MTX and placebo microimplants (without drug) were surgically implanted in the vitreous of the right and the left eyes, respectively, in each of the 8 New Zealand rabbits using minimally invasive technique. At each predetermined time points (days 5, 12, 19, and 33), ERG was conducted on 2 rabbits to evaluate the safety of the microimplants administered in each eye. ERG was carried out using 2 protocols, scotopic and photopic, on each eye prior to surgery (PS) and prior to euthanasia (PE) conditions. The safety of the microimplants was assessed using statistical analysis of the ERG data (B/A ratio analysis, oscillatory potential analysis, and Naka-Rushton analysis) and subsequently quantifying and comparing functional integrity of the retina between the PS and PE conditions of each eye. Results: Statistical analysis of the ERG data showed no change in retinal functional integrity because of the PLA-coated CS-based MTX microimplant and the placebo microimplant. ERG analysis also revealed absence of any evident bioelectrical dysfunction caused by the microimplants. Conclusion: ERGs were performed to determine whether the microimplants containing MTX and the placebo microimplants were associated with any profound retinal bioelectrical dysfunction that might be attributable to toxicity not apparent on histological studies of such eyes. The results shown in this report indicate that there were no such evident adverse effects of the microimplants or contained drug.

AB - Purpose: The purpose of this study is to noninvasively evaluate the safety and toxicity of a chitosan (CS) and polylactic acid (PLA)-based sustained-release methotrexate (MTX) intravitreal microimplant in normal rabbit eyes using electroretinography (ERG). Methods: PLA-coated CS-based microimplants containing 400 μg of MTX and placebo microimplants (without drug) were surgically implanted in the vitreous of the right and the left eyes, respectively, in each of the 8 New Zealand rabbits using minimally invasive technique. At each predetermined time points (days 5, 12, 19, and 33), ERG was conducted on 2 rabbits to evaluate the safety of the microimplants administered in each eye. ERG was carried out using 2 protocols, scotopic and photopic, on each eye prior to surgery (PS) and prior to euthanasia (PE) conditions. The safety of the microimplants was assessed using statistical analysis of the ERG data (B/A ratio analysis, oscillatory potential analysis, and Naka-Rushton analysis) and subsequently quantifying and comparing functional integrity of the retina between the PS and PE conditions of each eye. Results: Statistical analysis of the ERG data showed no change in retinal functional integrity because of the PLA-coated CS-based MTX microimplant and the placebo microimplant. ERG analysis also revealed absence of any evident bioelectrical dysfunction caused by the microimplants. Conclusion: ERGs were performed to determine whether the microimplants containing MTX and the placebo microimplants were associated with any profound retinal bioelectrical dysfunction that might be attributable to toxicity not apparent on histological studies of such eyes. The results shown in this report indicate that there were no such evident adverse effects of the microimplants or contained drug.

KW - chitosan

KW - Electroretinogram

KW - intravitreal

KW - methotrexate

KW - polylactic acid

KW - sustained drug delivery

UR - http://www.scopus.com/inward/record.url?scp=84994479645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994479645&partnerID=8YFLogxK

U2 - 10.1089/jop.2016.0006

DO - 10.1089/jop.2016.0006

M3 - Article

C2 - 27754738

AN - SCOPUS:84994479645

VL - 32

SP - 583

EP - 594

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 9

ER -